Skip to content

Processa Pharmaceuticals, Inc.: 10-Q filed 2025-11-06

What Processa Pharmaceuticals, Inc. reported in its quarterly report filed 2025-11-06 (fiscal Q3 2025): 28 published measures, 79 facts as tagged in accession 0001493152-25-021069.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-06
Fiscal period
fiscal Q3 2025
Accession
0001493152-25-021069 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Processa Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-307,584,576USD
At 2024-12-313,229,289USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-301,750,978USD
At 2024-12-311,533,118USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-305,833,598USD
At 2025-06-306,107,208USD
At 2025-03-313,526,608USD
At 2024-12-311,696,171USD
At 2024-09-303,720,785USD
At 2024-06-306,023,664USD
At 2024-03-318,883,366USD
At 2023-12-314,989,159USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-306,308,420USD
At 2024-12-311,191,325USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-3,436,573USD92
2025-01-01 to 2025-09-30-10,204,896USD273
2025-04-01 to 2025-06-30-3,933,918USD91
2025-01-01 to 2025-03-31-2,834,405USD90
2024-07-01 to 2024-09-30-3,384,703USD92
2024-01-01 to 2024-09-30-9,121,410USD274
2024-04-01 to 2024-06-30-3,010,326USD91
2024-01-01 to 2024-03-31-2,726,381USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-8,484,617USD273
2024-01-01 to 2024-09-30-8,997,321USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-3013,601,712USD273
2024-01-01 to 2024-09-307,185,832USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-3,244USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-97,424,095USD
At 2024-12-31-87,219,199USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-3047,525,522shares92
2025-01-01 to 2025-09-3024,838,859shares273
2024-07-01 to 2024-09-303,275,998shares92
2024-01-01 to 2024-09-302,909,941shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-3047,525,522shares92
2025-01-01 to 2025-09-3024,838,859shares273
2024-07-01 to 2024-09-303,275,998shares92
2024-01-01 to 2024-09-302,909,941shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.07USD/shares92
2025-01-01 to 2025-09-30-0.41USD/shares273
2024-07-01 to 2024-09-30-1.03USD/shares92
2024-01-01 to 2024-09-30-3.13USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.07USD/shares92
2025-01-01 to 2025-09-30-0.41USD/shares273
2024-07-01 to 2024-09-30-1.03USD/shares92
2024-01-01 to 2024-09-30-3.13USD/shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-09-304,113USD
At 2024-12-315,016USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-30734,009USD273
2024-01-01 to 2024-09-30474,466USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-3,488,843USD92
2025-01-01 to 2025-09-30-10,286,616USD273
2024-07-01 to 2024-09-30-3,424,853USD92
2024-01-01 to 2024-09-30-9,316,475USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-306,586,762USD
At 2024-12-311,879,154USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-301,750,978USD
At 2024-12-311,532,631USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-30727,172USD
At 2024-12-31880,880USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-3052,862,926shares
At 2024-12-313,702,628shares

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-12-3170,677USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-09-301,023,806USD
At 2024-12-31578,731USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-30278,342USD
At 2024-12-31687,829USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-3,436,573USD92
2025-01-01 to 2025-09-30-10,204,896USD273
2024-07-01 to 2024-09-30-3,384,703USD92
2024-01-01 to 2024-09-30-9,121,410USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,827,197USD92
2025-01-01 to 2025-09-304,589,925USD273
2024-07-01 to 2024-09-301,137,328USD92
2024-01-01 to 2024-09-303,759,781USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-01-01 to 2025-09-30903USD273
2024-01-01 to 2024-09-30481USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-09-305,589USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-153,708USD273
2024-01-01 to 2024-09-30400,093USD274

Inspect the source

Entity
Processa Pharmaceuticals, Inc. / CIK 0001533743
Captured
2026-09-20T09:16:31.348Z
SEC response SHA-256
5f3216d9024f2a7fc94b315f5bf243c7efb048273a6be394a2f74186d7af2a31

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001533743.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))